Skip to main content
Elekta logo

Elekta — Investor Relations & Filings

Ticker · EKTA ISIN · SE0000163628 LEI · 54930044O54BK617EP80 ST Manufacturing
Open in API
Filings indexed 1,124 across all filing types
Latest filing 2016-10-18 Regulatory Filings
Country SE Sweden
Listing ST EKTA

About Elekta

https://www.elekta.com/

Elekta is a company specializing in precision radiation medicine. It develops and provides clinical solutions, including equipment and software, for treating cancer and brain disorders. The company's portfolio features linear accelerators, the Elekta Unity MR-Linac system, Leksell Gamma Knife for stereotactic radiosurgery, and comprehensive brachytherapy solutions. Elekta also offers oncology informatics software to support treatment planning and clinical workflow. A key focus is advancing adaptive radiotherapy, a personalized approach that utilizes real-time imaging to precisely target tumors and minimize exposure to healthy tissue, aiming to improve patient outcomes.

Recent filings

Filing Released Lang Actions
All India Institute of Medical Science expands cancer care with advanced treatment devices from Elekta
Regulatory Filings Classification · 1% confidence The document announces a significant business transaction: All India Institute of Medical Science (AIIMS) acquiring advanced cancer treatment devices from Elekta. It details the order booking period ('second quarter of Elekta's fiscal year') and includes contact information for Financial Communication, concluding with a statement that the information is 'obliged to make public pursuant to the EU Market Abuse Regulation'. This structure strongly suggests a regulatory disclosure regarding a major contract or business development, rather than a standard financial report (10-K, IR) or an earnings release (ER). Since it is a specific, material announcement that doesn't fit the other specific categories (like M&A, Capital Change, or Dividend), it falls best under the general 'Regulatory Filings' category (RNS) as a catch-all for required market disclosures that aren't explicitly defined elsewhere, or potentially a 'Capital/Financing Update' (CAP) if the focus was purely on the financing aspect, but here the focus is the contract itself. Given the context of mandatory disclosure under market regulations, RNS is the most appropriate fallback.
2016-10-18 English
Installation of Elekta’s sixth high-field MR-adaptive linear accelerator initiated at The Christie
Regulatory Filings Classification · 1% confidence The document is a press release dated October 12, 2016, announcing the initiation of installation of a new MR-adaptive linear accelerator system at The Christie hospital, involving Elekta and Philips. It details technological advancements, research consortium involvement, and quotes executives and doctors. The final paragraph states: "The above information is such that Elekta AB (publ) shall make public in accordance with the Securities Market Act and/or the Financial Instruments Trading Act. The information was published at 07:30 CET on October 12, 2016." This structure strongly indicates a formal regulatory announcement intended for public disclosure, rather than a detailed financial report (like 10-K or IR) or a transcript. Since it is a general announcement of corporate activity and progress that doesn't fit the specific categories like Director's Dealing (DIRS), Dividend (DIV), or Capital Change (CAP), it falls best under the general regulatory announcement category, which is RNS (Regulatory Filings), or potentially an Investor Presentation (IP) if it were a slide deck, but the format is clearly a news release/announcement. Given the context of mandatory disclosure under securities acts, RNS is the most appropriate general regulatory filing code.
2016-10-12 English
Installation av Elektas sjätte MR-adaptiva högfälts-linjäraccelerator påbörjad hos The Christie
Regulatory Filings Classification · 1% confidence The document is a press release announcing the start of installation for a new medical device (MR-linac) at The Christie hospital, involving Elekta and Philips. It details the technology, the research focus (lung cancer), and the involvement of a research consortium. The text concludes with contact information and a standard disclosure stating: "Informationen är sådan som Elekta AB (publ) ska offentliggöra enligt lagen om handel med finansiella instrument och/eller lagen om värdepappersmarknaden. Informationen lämnades för offentliggörande den 12 oktober 2016 kl. 07:30 CET." This structure strongly indicates a formal regulatory announcement or press release intended for public disclosure regarding company activities, rather than a comprehensive financial report (10-K, IR) or a specific shareholder communication (DEF 14A, AGM-R). Since it is a general announcement of corporate news that doesn't fit the specific categories like ER, CAP, or DIV, the most appropriate classification is the general regulatory announcement fallback category, RNS (Regulatory Filings). The document length (10193 chars) is substantial, ruling out RPA based on the 'MENU VS MEAL' rule, as this is the content itself, not just an announcement of content.
2016-10-12 Swedish
Data presented at ASTRO underscore the promise of Elekta’s high-field MR-adaptive linear accelerator as a transformative advance in radiation therapy
Regulatory Filings Classification · 1% confidence The document is a press release from Elekta dated September 29, 2016, announcing data presented at the American Society for Radiation Oncology (ASTRO) 2016 Annual Meeting regarding their MR-linac technology. It details clinical findings, presentations, and future outlook. The text concludes with contact information and a statement about public disclosure according to securities acts, indicating it is a formal corporate announcement. Since it is an announcement of clinical/research progress and not a formal periodic financial report (like 10-K or IR), nor a transcript (CT), nor a specific management/board change (MANG), it best fits the general category for corporate news releases that don't fit elsewhere, which is Regulatory Filings (RNS), or potentially an Investor Presentation (IP) if it were structured as a presentation deck, but given the press release format summarizing conference activity, RNS is the most appropriate general regulatory announcement category.
2016-09-29 English
Data som presenterades på ASTRO stärker bilden av att Elektas MR-adaptiva högfälts-linjäraccelerator har potential att förändra strålterapin
Environmental & Social Information Classification · 1% confidence The document is a press release from Elekta dated September 29, 2016, announcing updates and data presented at the ASTRO (American Society for Radiation Oncology) annual meeting regarding their MR-linac technology. It details presentations, abstracts, and clinical potential. The text concludes with contact information and a statement about the information being made public according to financial instrument laws, indicating it is a formal corporate announcement. Since it is not a full annual report (10-K), a quarterly report (IR), a specific earnings release (ER), or a proxy statement (DEF 14A), and it is a general corporate update/announcement, it best fits the 'Regulatory Filings' (RNS) category as a general regulatory/corporate disclosure, or potentially an Investor Presentation (IP) if it were structured as slides, but given the press release format summarizing external conference activity, RNS is the most appropriate general disclosure category.
2016-09-29 Swedish
Elektas nya Leksell Vantage Stereotactic System förbättrar visualiseringsteknik och arbetsflöden inom neurokirurgi
Regulatory Filings Classification · 1% confidence The document is a press release written in Swedish announcing the introduction of a new medical device, the Leksell Vantage Stereotactic System, at a conference. It details product features, benefits, and future availability. The concluding paragraph states: "Informationen är sådan som Elekta AB (publ) ska offentliggöra enligt lagen om handel med finansiella instrument och/eller lagen om värdepappersmarknaden. Informationen lämnades för offentliggörande den 28 september 2016 kl. 07:30 CET." This language strongly indicates a mandatory regulatory disclosure regarding a significant event or product launch, which typically falls under general regulatory announcements or news releases that don't fit the specific financial report categories (10-K, IR, ER, etc.). Given the options, 'Regulatory Filings' (RNS) is the most appropriate fallback for a general, mandatory regulatory announcement that is not a specific financial report, dividend notice, or management change.
2016-09-28 Swedish

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.